The Drug-Induced Respiratory Disease Website and App
Frequency - Incidence
Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases
Evidence level/grade
Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic
Capillary leak syndrome (CLS)
Publications
Casadei Gardini A, Aquilina M, Oboldi D, Lucchesi A, Carloni S, Tenti E, Burgio MA, Amadori D, Frassineti GL
Separate episodes of capillary leak syndrome and pulmonary hypertension after adjuvant gemcitabine and three years later after nab-paclitaxel for metastatic disease.
BMC cancer 2013 Nov 12;13;542 — 2013 Nov 12 — 542
Cure of gemcitabine-induced systemic capillary leak syndrome without corticosteroids.
Journal of B.U.ON. : official journal of the Balkan Union of Oncology 2009 Oct-Dec;14;728-9 — 2009 Oct-Dec — 728-9
Gemcitabine: vascular toxicity and prothrombotic potential.
Expert opinion on drug safety 2008 Nov;7;703-16 — 2008 Nov — 703-16
Gemcitabine-induced chronic systemic capillary leak syndrome: a life-threatening disease.
Clinical oncology (Royal College of Radiologists (Great Britain)) 2006 Feb;18;90-1 — 2006 Feb — 90-1
Severe gemcitabine-induced capillary-leak syndrome mimicking cardiac failure in a patient with advanced pancreatic cancer and high-risk cardiovascular disease.
Clinical oncology (Royal College of Radiologists (Great Britain)) 2004 Dec;16;577-9 — 2004 Dec — 577-9
Gemcitabine-induced systemic capillary leak syndrome.
Annals of oncology : official journal of the European Society for Medical Oncology 2001 Nov;12;1651-2 — 2001 Nov — 1651-2